Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.33 |
| ▸ | FOS | P01100 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | JUN | P05412 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3026929 | 0.88 | ALDH1A1 (0.34) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL3037684 | 0.85 | ALOX15 (0.33) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL12712736 | 0.84 | FOS (0.37) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL3044667 | 0.80 | LMNA (0.40) | LMNAALOX15ALOX12FOSTTR | |
| SCHEMBL1021545 | 0.79 | PTGS2 (0.37) | CA2PTGS2CALM1 | |
| SCHEMBL13015950 | 0.77 | ERN1 (0.39) | FOSTTRJUNCA2PTGS2 | |
| SCHEMBL13220709 | 0.75 | PTGS2 (0.57) | LMNAFOSTTRJUNNR3C1 | |
| SCHEMBL13347308 | 0.73 | PRKDC (0.39) | LMNA | |
| SCHEMBL5782140 | 0.72 | ALDH1A1 (0.46) | PTGS2 | |
| SCHEMBL920600 | 0.71 | HSD17B10 (0.41) | ALOX15CA2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100217001-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100217001-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100217001-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2202233-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
| EP-2202233-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217001-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | CYP3A4, CYP4B1, CYP51A1 | LMNA 4426/4885ALOX15 1335/4885ALOX12 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.